Insect Cell/Baculovirus Protein Expression Services – Providing Efficient and Reliable Research Support

Background

Cervical cancer poses a significant global health challenge. AtaGenix, a leader in biotechnology, has developed the groundbreaking ENO1 monoclonal antibody (ENO1mAb) to target α-enolase (ENO1), a critical enzyme driving tumor metabolism and progression in cervical cancer.

Figure 1. Title Page Highlighting AtaGenix's Research

Study Overview

AtaGenix spearheaded the development of ENO1mAb using advanced hybridoma technology, expertly expressed in insect cells. By integrating folic acid-conjugated PLGA nanoparticles—crafted by our team—this innovative delivery system ensures targeted ENO1 inhibition, dramatically reducing cervical cancer cell invasion, proliferation, and clone formation.

AtaGenix's Key Contributions and Results

Through AtaGenix's cutting-edge research, ENO1mAb delivers exceptional outcomes:

• AtaGenix's ENO1mAb blocks plasminogen activation, halting tumor migration and invasion.
• Our technology inhibits glycolysis, significantly reducing lactic acid and pyruvate levels.
• AtaGenix suppresses cell proliferation and clone formation in cervical cancer lines like SiHa and Hela.
• Our proprietary FA-SS-PLGA nanoparticles enhance intracellular delivery, maximizing therapeutic potential.

Figure 2. AtaGenix's ENO1mAb Inhibitory Effects on SiHa Cells

Significance

AtaGenix's pioneering work with ENO1mAb sets a new standard in cervical cancer treatment, leveraging our expertise in antibody development and nanoparticle technology. This breakthrough opens transformative possibilities for cancer therapy. Collaborate with AtaGenix to unlock your next breakthrough.

Contact AtaGenix for Your Project